^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    GPRC5D inhibitor

    Related drugs:
    7d
    A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=150, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    Lynozyfic (linvoseltamab-gcpt)
    7d
    EMN37 fitfix: Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. (clinicaltrials.gov)
    P2, N=150, Recruiting, European Myeloma Network B.V. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Darzalex (daratumumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    8d
    BP42233: A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM) (clinicaltrials.gov)
    P1, N=225, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion • First-in-human
    |
    forimtamig (RG6234)
    9d
    MonumenTAL-3: A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment (clinicaltrials.gov)
    P3, N=864, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Jun 2029 --> May 2028 | Trial primary completion date: Feb 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    dexamethasone • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Talvey (talquetamab-tgvs) • dexamethasone injection
    9d
    MajesTEC-7: A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P3, N=1590, Recruiting, Janssen Research & Development, LLC | N=568 --> 1590
    Enrollment change
    |
    lenalidomide • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    9d
    MAGENTA: Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=25, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    dexamethasone • Talvey (talquetamab-tgvs) • mezigdomide (CC-92480)
    14d
    TRIlogy-5: A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=700, Not yet recruiting, Janssen Research & Development, LLC
    New P3 trial
    |
    lenalidomide • ramantamig (JNJ-5322) • Tecvayli (teclistamab-cqyv)
    21d
    Talisman: A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events (clinicaltrials.gov)
    P2, N=210, Recruiting, Janssen Research & Development, LLC | N=130 --> 210
    Enrollment change
    |
    Talvey (talquetamab-tgvs)
    23d
    Talquetamab in Patients With Refractory Generalized Myasthenia Gravis (clinicaltrials.gov)
    P=N/A, N=2, Not yet recruiting, First Affiliated Hospital of Chongqing Medical University
    New trial
    |
    Talvey (talquetamab-tgvs)
    28d
    A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma (clinicaltrials.gov)
    P1, N=87, Recruiting, Sanofi | Trial completion date: May 2029 --> May 2031 | Trial primary completion date: Nov 2028 --> May 2031
    Trial completion date • Trial primary completion date • First-in-human
    2ms
    A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=150, Not yet recruiting, Regeneron Pharmaceuticals
    New P1/2 trial • First-in-human
    |
    Lynozyfic (linvoseltamab-gcpt)
    2ms
    A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy (clinicaltrials.gov)
    P2, N=17, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2026 --> Oct 2027 | Trial primary completion date: Oct 2026 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    Talvey (talquetamab-tgvs)